Celldex inks tech deal to advance cancer vaccines; AZ's expanded China focus pays off

> In his first interview as CEO, GlaxoSmithKline's Andrew Witty told the Financial Times he intends to "diversify and derisk" the company. GSK report

> Celldex Therapeutics has struck a deal to use 3M's toll-like receptor (TLR) agonist compounds--useful as vaccine adjuvants--for a slate of new oncology vaccines in development. Report

> Big Pharma has been talking a lot lately about pushing into emerging markets, seeing as that's where the biggest growth prospects lie. But how, exactly, does a drugmaker go about doing that? The Wall Street Journal lifts the curtain on AstraZeneca's forays into China, particularly beyond the typical commercial strongholds in Beijing and Shanghai. Report

> GlaxoSmithKline is touting new, late-stage data that demonstrates how its experimental pediatric vaccine Synflorix effectively protects children from pneumococcal disease. Vaccine report

> Iomai has racked up more positive data for its vaccine patch to prevent traveler's diarrhea. Iomai report

> Seemingly tireless FDA critique-man Sen. Charles Grassley now has his eye on GlaxoSmithKline. He's asking the FDA to review GSK's antidepressant Paxil, which just emerged from a years-long probe in the U.K. Report

And Finally... From scientist-in-chief to top chief? Frank Torti, a cancer researcher who joined FDA two months ago, may be in line for the commissioner's job. Report

Suggested Articles

Across its 15-year history, Omega Funds has a hand in a clutch of high-profile biotechs such as Editas Medicine and Juno Therapeutics.

After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.

The data position Leo to file for approval of the Dupixent rival in atopic dermatitis next year.